PDS Biotechnology Q2 EPS $(0.37), Inline; Cash and Equivalents $60.6M Sufficient to Fund R&D Aug. 2024
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology reported Q2 losses of $(0.37) per share, in line with analyst consensus. This is an 85% increase in losses from the same period last year. The company has cash and equivalents of $60.6M, which it believes is sufficient to fund operations and R&D for the next 12 months.
August 14, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
PDS Biotechnology reported increased losses in Q2, but has sufficient cash to fund operations and R&D for the next year.
While the increased losses might negatively impact the stock, the company's strong cash position and ability to fund its operations and R&D for the next year could offset this. Therefore, the short-term impact on the stock is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100